BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31107718)

  • 21. Maximum tumor diameter: a simple independent predictor for biochemical recurrence after radical prostatectomy.
    Fukuhara H; Kume H; Suzuki M; Fujimura T; Enomoto Y; Nishimatsu H; Ishikawa A; Homma Y
    Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):244-7. PubMed ID: 20567255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
    Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer.
    Bolton DM; Ta A; Bagnato M; Muller D; Lawrentschuk NL; Severi G; Syme RR; Giles GG
    World J Urol; 2014 Apr; 32(2):431-5. PubMed ID: 23824175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer.
    Choi SY; Chi BH; Lim B; Kyung YS; You D; Jeong IG; Song C; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):537-543. PubMed ID: 31915914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer.
    Kang HW; Jung HD; Lee JY; Kwon JK; Jeh SU; Cho KS; Ham WS; Choi YD
    Asian J Androl; 2016; 18(3):480-4. PubMed ID: 26178393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification.
    Abdollah F; Sun M; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Fossati N; Castiglione F; Freschi M; Karakiewicz P; Rigatti P; Montorsi F; Briganti A
    Urol Oncol; 2013 Nov; 31(8):1497-503. PubMed ID: 22591746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
    Mizuno R; Nakashima J; Mukai M; Okita H; Kosugi M; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M
    BJU Int; 2009 Nov; 104(9):1215-8. PubMed ID: 19389009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subclassification of pathologically organ-confined (pT2) prostate cancer does not significantly predict postoperative outcomes in Korean males.
    Lee MH; Lee S; Hong SK; Byun SS; Lee SE
    Investig Clin Urol; 2020 Jan; 61(1):35-41. PubMed ID: 31942461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
    Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
    Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
    Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score.
    Hansen J; Bianchi M; Sun M; Rink M; Castiglione F; Abdollah F; Steuber T; Ahyai SA; Steurer S; Göbel C; Freschi M; Montorsi F; Shariat SF; Fisch M; Graefen M; Karakiewicz PI; Briganti A; Chun FK
    BJU Int; 2014 Mar; 113(3):399-407. PubMed ID: 24053339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting survival of men with recurrent prostate cancer after radical prostatectomy.
    Dell'Oglio P; Suardi N; Boorjian SA; Fossati N; Gandaglia G; Tian Z; Moschini M; Capitanio U; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
    Eur J Cancer; 2016 Feb; 54():27-34. PubMed ID: 26707594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score.
    Song W; Kwon YS; Jeon SS; Kim IY
    Asian J Androl; 2017; 19(1):20-25. PubMed ID: 26620454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific spatial distribution patterns of tumor foci are associated with a low risk of biochemical recurrence in pT2pN0R0 prostate cancer.
    Eminaga O; Abbas M; Bettendorf O; Semjonow A
    World J Urol; 2021 May; 39(5):1499-1507. PubMed ID: 32591903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 Tumour-Nodes-Metastasis staging system.
    van Oort IM; Witjes JA; Kok DE; Kiemeney LA; Hulsbergen-Van De Kaa CA
    BJU Int; 2008 Aug; 102(4):438-41. PubMed ID: 18336608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving the prediction of biochemical recurrence after radical prostatectomy with the addition of detailed pathology of the positive surgical margin and cribriform growth.
    Remmers S; Hollemans E; Nieboer D; Luiting HB; van Leenders GJLH; Helleman J; Roobol MJ
    Ann Diagn Pathol; 2022 Feb; 56():151842. PubMed ID: 34717190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Index tumor location affected early biochemical recurrence after radical prostatectomy in patients with negative surgical margin: a retrospective study.
    Ogata Y; Akatsuka J; Endo Y; Mikami H; Yanagi M; Takeda H; Toyama Y; Yamamoto Y; Kimura G; Kondo Y
    BMC Urol; 2024 May; 24(1):108. PubMed ID: 38762458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression.
    Schiffmann J; Salomon G; Tilki D; Budäus L; Karakiewicz PI; Leyh-Bannurah SR; Pompe RS; Haese A; Heinzer H; Huland H; Graefen M; Tennstedt P
    Urol Oncol; 2017 May; 35(5):243-249. PubMed ID: 28161322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.